Studies from genetic modification and spontaneous mutations show that C-type natriuretic peptide (CNP) signalling plays an essential part in postnatal endochondral growth, but measurement of CNP proteins and changes in their abundance in tissues and plasma during normal growth has not been reported. Using rodent pups with GH deficiency, we now describe the pharmacodynamic response of CNP and rat amino-terminal proCNP (NTproCNP) in plasma and tissues, and relate these to changes in linear growth (nose-tail length, tibial length and tibial growth plate width) during the course of 1 week of GH or saline (control) administration. Compared with saline, significant increases in plasma and tissue CNP forms were observed after 24 h in GH-treated pups and before any detectable change in linear growth. Whereas CNP abundance was increased in most tissues (muscle, heart and liver) by GH, enrichment was the greatest in extracts from growth plates and kidney. Plasma and tissue concentrations in GH-treated pups were sustained or further increased at 1 week when strong positive associations were found between plasma NTproCNP and linear growth or tissue concentrations. High content of NTproCNP in kidney tissue strongly correlated with plasma concentrations, which is consistent with previous data showing renal extraction of the peptide. In showing a prompt and significant increase in CNP in tissues driving normal endochondral growth, these findings provide further rationale for CNP agonists in the treatment of growth disorders resistant to current therapies and support the use of CNP concentrations as biomarkers of linear growth.
Introduction
C-type natriuretic peptide (CNP) belongs to a family of peptides recognised for their cardioprotective actions within the heart (Potter et al. 2006) and vasculature (Suga et al. 1992) . Considered to have a long lineage dating back to jawless fish (Takei et al. 2011) , CNP is expressed in all mammals studied to date and in a wide range of tissues (Minamino et al. 1993) where the hormone, acting locally via its specific receptor (natriuretic peptide receptor B; NPRB), is thought to regulate cellular proliferation and maturation (Potter et al. 2006) . Convincing evidence from the last decade shows that CNP is essential for postnatal skeletal growth (Chusho et al. 2001) . For example, contrived (Olney 2006) or spontaneous genetic modifications within the CNP signalling pathway in rodents (Potter et al. 2006) , cattle (Koltes et al. 2009 ) and humans (Bartels et al. 2004 , Moncla et al. 2007 ) uniformly and concordantly profoundly affect linear growth velocity. That this may also be true of normal growth is suggested by findings from genome-wide association studies linking the adult height of humans with several genes affecting CNP's activity (Lango Allen et al. 2010) . How CNP stimulates skeletal growth is still to be clarified, but in vitro data indicate growth-promoting actions of CNP in all zones of the growth plate, including recruitment of chondroblasts (Woods et al. 2007) , chondrocyte proliferation (Mericq et al. 2000) and hypertrophy (Kake et al. 2009 , Yasoda et al. 2009 ) (the dominant action), as well as stimulating matrix formation (Yasoda et al. 2004 , Krejci et al. 2005 .
After intracellular processing of the CNP prohormone (CNP 1-103), both bioactive CNP 53 and the (presumably bioinactive) amino-terminal component, amino-terminal proCNP (NTproCNP), are secreted in equimolar amounts (Wu et al. 2003) . Bioactive CNP forms are rapidly degraded at source (and in plasma where the half-life of CNP 22 is w2 . 5 min in humans (Hunt et al. 1994) 
) in contrast to
NTproCNP which is likely to be resistant to enzyme hydrolysis or uptake by clearance receptors (Potter et al. 2006) and is readily measured in the circulation (Prickett et al. 2005) . We have found that plasma concentrations of NTproCNP are closely correlated with concurrent growth velocity throughout childhood (Olney et al. 2007 , Prickett et al. 2008 , suggesting that CNP production within growth plates or closely related tissue is age dependent and acts as a driver of linear growth after birth. However, no study has examined the peptide concentrations within tissues with potential to affect skeletal growth, or how the tissue concentrations may change or relate to plasma concentrations and the growth process itself. These relationships are important to quantitate in a setting of changing tissue growth rates -preferably in GH deficient models receiving GH that is considered to be a major endocrine regulator of postnatal linear growth in mammals. Hypothesizing that CNPs are enriched in growth plates relative to other tissues, and are increased when linear growth is stimulated, we have now studied the pharmacodynamic response of tissue and plasma CNP and NTproCNP during a period of rapid growth initiated by GH administration in the spontaneous Dwarf rat. This animal model of GH deficiency (GHD) has undetectable levels of GH in serum and pituitary due to a splice variant mutation in the GH gene (Takeuchi et al. 1990) and is fully responsive to exogenous GH treatment (Nogami et al. 1992 ).
Materials and Methods
All studies were approved by the animal ethics committee of the University of Otago, Christchurch.
Animal studies
GHD Sprague-Dawley rats (22) were bred and housed in light (12 h daily) and temperature (20-22 8C) controlled rooms where they received tap water and standard diet (Rat and Mouse Pellets, Specialty Feeds, Glen Forrest, WA, Australia) ad libitum. Rats were weaned on day 21. At age 28 days, groups of male GHD rats (nZ6 for each treatment arm) received at 1000 h daily an s.c. injection of either hGH (0 . 3 mg/kg live weight, Norditropin, Novo Nordisk, Denmark) or vehicle (saline, littermate controls). The dose and duration of GH treatment were chosen in light of previous reports (Nogami et al. 1992) of the pattern and dose-response curve that was linear over the range of 1 . 35-5 mg/kg per day and identical in both male and female pups. Live weight and nose-tail length were measured daily, and growth velocity was calculated and expressed as millimetre per day. After 24 h (day 1) or 1 week (day 7) of treatment, the rats were killed (4 h after the last injection) and blood (1 ml) was drawn by cardiac puncture into ice-cold blood collection tubes (1 . 8 mg/ml K 2 EDTA, Vacutainer; Becton-Dickinson, Plymouth, UK). Plasma was separated by centrifugation and stored at K20 8C before analysis. The heart, liver, kidneys and left tibia and ulna bones were promptly excised and snap frozen under liquid N 2 for later protein analysis. The right anterior tibia was then excised and fixed in phosphate-buffered formaldehyde before embedding for growth plate histology. Frozen tissues were stored at K70 8C before analysis.
Extraction of CNPs from tissues
Frozen tissue (0 . 1-0 . 3 g) was crushed by impact in a stainless steel chamber surrounded by dry ice, placed in 10 ml boiling water containing 0 . 01% triton-X 100 for 5 min, acidified with acetic acid, and homogenised before extraction on Sep-Pak C18 cartridges (Waters Corporation, Milford, MA, USA), as previously described for ovine pituitary tissue (Yandle et al. 1993) . The extracts were re-suspended in either assay buffer for RIA or 20% CH 3 CN in 0 . 1% TFA before subjecting them to size exclusion HPLC (G2000, Toyosoda, Tokyo, Japan). To ensure the inclusion of both proximal and distal epiphyseal tissues, the entire bone head (separated from the shaft at the metaphysis) was excised and extracted. Values are expressed as fentomole per gram of tissue extracted.
Histology
Rat tibia was fixed in phosphate-buffered formaldehyde for 20 h, then decalcified in a solution containing 1% EDTA and 1 M HCl for 1 h and embedded in paraffin. Five-micrometrethick sagittal sections were cut and mounted on glass slides, deparaffinised, rehydrated and stained with haematoxylin and eosin. Tibia length and growth plate widths were determined by averaging a minimum of six measurements using ImageJ software (v1.42q, Wayne Rasband NIH, USA) on images captured using Olympus 1X70 inverted microscope with camera.
RIA for rat NTproCNP
NTproCNP was measured by RIA using a sheep antiserum raised against human proCNP(1-81) that recognises a C-terminal epitope in the region of proCNP(38-50) where human, mouse, rat and ovine amino acid sequences are identical. Peptide standards were made from synthetic human proCNP(36-50) (Mimotopes, Clayton, VIC, Australia) taking into account the purity data supplied. All standards, sample extracts, antisera and tracer solutions were made up in pH 7 . 4 assay buffer (Yandle et al. 1986) . Fifty microlitres of sample extract or 0 . 5-1000 pmol/l proCNP(36-50) standard (all in duplicate) were incubated with 50 ml antiserum (Sheep 43, 1:3000 diluted antiserum/assay tube) for 22 h, followed by addition of 50 ml tracer solution 125 I]Tyr37 were separated by a solid-phase second antibody method (Sac-cell, Donkey-Anti Rabbit, IDS Ltd, England). This assay has a detection limit of 0 . 4 pmol/l and an ED 50 of 9 . 6 pmol/l. Intra-and inter-assay coefficients of variation were 2 . 1 and 6 . 3% respectively at 16 pmol/l.
RIA for CNP
The sequence of CNP 22 (CNP 82-103) is identical in all mammals studied to date. CNP was assayed as described previously (Yandle et al. 1993) . This assay has a detection limit of 0 . 5 pmol/l and an ED 50 of 7 . 2 pmol/l. Intra-and interassay coefficients of variation were 5 . 7 and 6 . 2% respectively at 9 pmol/l.
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Statistical analysis
Data were presented as meanGS.E.M., where appropriate. Student's t-tests were used to analyse differences in peptide and histomorphological indices between GH-and salinetreated littermates. Repeated-measures ANOVA was used to assess changes in physical measurements. Spearman correlation coefficients were used to test the associations between linear growth velocity and circulating and tissue concentrations of CNP forms. Statistical significance was assumed when P!0 . 05.
Results
Growth
Before treatments, the mean body weights (37 . 9G2 vs 37 . 4G1 . 9 g in saline and GH treatment groups respectively) did not differ. On day 1, GH-treated rats gained significantly more weight than saline-treated control littermates (P!0 . 05, Table 1 ). Nose to tail length was significantly increased by day 4 of GH treatment (FZ22 . 4, P!0 . 001), and thereafter continued to exceed control values (data not shown). As shown in Fig. 1A , nose-tail growth velocity was significantly greater (P!0 . 001) in GH-treated pups on day 7, as was tibial length (Table 1 , P!0 . 05). Compared with controls, no significant increase in tibial growth plate width was evident on day 1 of GH treatment in contrast to day 7 when expansion of both proliferative and hypertrophic zones of the growth plate was significantly increased in pups receiving GH (Table 1 and Fig. 2 ).
Plasma CNP forms and relation to treatment
Analysis of NTproCNP immunoreactivity in rat plasma using size exclusion HPLC (Fig. 3A) identified a dominant peak eluting in the position consistent with the presence of the 5 kDa amino-terminal proCNP (proCNP1-50).
On day 1, plasma concentrations of CNP (3 . 9G0 . 2 vs 3 . 1G0 . 1 pmol/l) and NTproCNP (116G5 vs 84G 2 pmol/l) were both significantly increased respectively by GH treatment compared with saline control (Fig. 1B and C, P!0 . 001 for both), whereas nose-tail growth velocity (Fig. 1A) did not differ. At the completion of the study (day 7), these changes were further enhanced (CNP 4 . 6G0 . 3 vs 3 . 1G0 . 1 pmol/l; NTproCNP 174G9 vs 101G4 pmol/l).
In saline-treated controls, plasma CNP did not change, but a significant increase in NTproCNP was observed on day 7 (P!0 . 001, Fig. 1C ).
Relating growth indices to plasma NTproCNP in individual pups (both control and GH groups combined) shows a close coupling with nose-tail growth velocity (rZ 0 . 72, P!0 . 001, Fig. 4A ), proximal tibia growth plate width (rZ0 . 69, P!0 . 001, Fig. 4B ), and width of the hypertrophic zone (rZ0 . 64, P!0 . 001, Fig. 4C ). There was also a close association of plasma CNP (Fig. 4D-F ) with nose-tail growth velocity (rZ0 . 67, P!0 . 001), proximal tibial growth plate width (rZ0 . 67, P!0 . 001), and width of the proximal tibial hypertrophic zone (rZ0 . 65, P!0 . 001).
Tissue CNPs and response to treatment
Analysis of NTproCNP immunoreactivity in rat tibial epiphyseal tissue extract using HPLC is shown in Fig. 3B . As found in plasma (Fig. 3A) , a single peak eluting in the Table 2 , in saline-treated pups, concentrations (fmol/g) of CNP were the highest in proximal tibial extracts on both days 1 and 7. High concentrations of NTproCNP were also found in proximal tibial extracts, but on day 7, the concentration of NTproCNP in kidney exceeded that in other tissues. CNP concentrations of the four skeletal tissues extracted from saline-treated pups exceeded those of other tissues (kidney excepted) on both days 1 and 7 (Table 2) .
Response patterns of tissue CNP and NTproCNP to GH treatment were similar on days 1 and 7 (Table 2) . Whereas GH treatment increased CNP and NTproCNP in most tissues, the highest concentrations were observed in extracts of proximal tibia, distal ulnar and renal tissues on both days 1 and 7. A significant association of proximal tibial growth plate content of NTproCNP with the width of this plate's hypertrophic zone (rZ0 . 74, PZ0 . 01) was found on day 7, but not on day 1. The association between proximal tibial growth plate CNP content and hypertrophic growth plate width on day 7 was not significant (rZ0 . 39, PZ0 . 2).
Comparing individual tissue responses to GH (Table 2) , the greatest increment (D %) was in the renal concentration of NTproCNP. Of note, renal concentrations of both CNPs increased with time (day 7 vs day 1) in both control and GH-treated pups (Table 2) .
Correlations between tissue and circulating peptides
When the concentrations of tissue CNPs and concurrent plasma concentrations were compared in individuals (both control and GH groups combined), significant positive correlations (distal tibia excepted) were found between plasma NTproCNP and NTproCNP concentrations of epiphyseal tissues (proximal tibia: rZ0 . 62, P!0 . 005; distal tibia: rZ0 . 28, PZNS and proximal ulna: rZ0 . 47, P!0 . 05, Fig. 5A-C) . Strong associations were also found with kidney (rZ0 . 95, P!0 . 001), heart (rZ0 . 72, P!0 . 001) and skeletal muscle (rZ0 . 67, P!0 . 005) tissues (Fig. 5D-F ). Of note, whereas similar positive relationships were found between plasma CNPs and kidney (rZ0 . 68, P!0 . 001), muscle (rZ0 . 62, P!0 . 005), liver (rZ0 . 61, P!0 . 005) and heart (rZ0 . 54, P!0 . 05), associations with epiphyseal CNP content were not significant.
Discussion
Although the CNP signalling pathway is known to play an essential part in postnatal linear growth, this is the first report to show that products of CNP gene expression increase within 24 h of commencing GH treatment in any species. Furthermore, the dynamic responses of plasma concentration of NTproCNP, growth plate expansion and growth plate content of CNPs are positively related, underpinning the view that the hormone's production is intimately involved in linear growth. Previous studies indicate that over or under CNP activity, in contrast to some other essential growth factors in cartilage (Cohen 2006) , have concordant effects on the skeletal phenotype without causing skeletal deformity (Kake et al. 2009 , Olney et al. 2009 ). These observations are consistent with the findings in vitro showing that CNP acts positively at multiple sites (and at different phases) of chondrogenesis -the combined effects of which greatly augment the orderly expansion (Kake et al. 2009 ) of the growth plate. Despite these recent advances, there is scant information on the concentrations of the CNP proteins themselves in tissues and plasma. Using GH (the principle endocrine factor regulating postnatal linear growth in mammals), we show here that stimulating chondrogenesis in GHD rodent pups rapidly increases both tissue and plasma CNP forms -effects that were sustained over the course of the 7-day study. Of note, both CNP and NTproCNP had increased significantly in plasma within 24 h at which time neither nose-tail growth velocity nor change in growth plate morphology differed from measurements made in control pups given saline. Thus, significant increase in circulating levels precedes detectable changes in linear growth. However, by day 7, the expected somatic effects of GH were observed (Nogami et al. 1992) . The strong associations linking growth parameters to timematched plasma NTproCNP concentrations provide further support to the in vitro studies and indicate that CNP proteins are likely to materially contribute to sustained endochondral growth. In this context, it should be noted that this association (skeletal growth and plasma NTproCNP) has been established in lambs (using metacarpal growth (Prickett et al. 2005) ), human neonates (tibial growth (Prickett et al. 2008) ), children (height, i.e. largely vertebral and lower limb growth (Prickett et al. 2005 , Olney et al. 2009 ) and now in rodents (nose-tail growth, tibial length and growth plate width). Presumably all growth plates involved in endochondral growth contribute to plasma CNP concentrations to varying degrees, whereas only selective bones contribute to height or body length.
Nonetheless, the r values (0 . 69 linking plasma concentration with proximal tibial growth plate width and 0 . 72 with nosetail growth velocity) are surprisingly close and presumably reflect the systemic and global effects of restoring GH in the GH-deficient state. Whereas CNP proteins have been quantified in a range of different tissues (Minamino et al. 1991 , Prickett et al. 2005 , McNeill et al. 2009 ), to our knowledge, the effect of GH on tissue levels has not been studied. In this study, CNP and NTproCNP were detected in all tissues examined in saline-treated (control) rats and were found to be most abundant in tissues from the proximal tibial and distal ulnar heads, and kidney. Concentrations of NTproCNP in these tissues were two-to three-fold higher than those found in skeletal muscle, heart and liver, and presumably reflect residual GH secretion (Nogami et al. 1992) . Compared with saline control values, concentrations of both CNP forms were significantly increased by GH on day 1 in most tissues. Again, the highest concentrations were observed in proximal tibia, distal ulnar and kidney tissue, and were much higher than those in muscle, heart or liver extracts. Profiles and tissue response patterns on day 7 were closely similar except for renal tissue concentration of NTproCNP that was augmented some 1 . 7-fold (day 7 vs day 1) in pups receiving GH. Thus, the CNP-enriched tissues as measured on day 1 (tibia, ulnar and kidney) also showed the highest concentrations after 7 days of receiving GH. Consistently lower concentrations of both CNP and NTproCNP were found in tissues of the distal tibia and proximal ulnar. It is interesting to note that growth rates of the distal tibial (and proximal radial) plates, as measured by tetracycline labelling by Breur et al. (1997) , are reportedly much reduced in normal rodent pups compared with those of the proximal tibia and distal radius. Remarkably, relative to values in the proximal tibia, the abundance of NTproCNP in the distal tibial tissue on day 1 (50%) and day 7 (39%) in salinetreated controls approximates the relative growth rates (56 and 47% respectively) at these times measured by Breur's group. Corresponding values in NTproCNP concentration during GH treatment (36 and 34% respectively) were slightly lower. Together, these differential responses among individual growth plates provide further support for CNP's role in driving growth plate expansion in vivo. The similar temporal response evident in plasma and tissues is most likely a consequence of enhanced CNP gene expression since the alternative (uptake, or sequestration of plasma into tissues) is implausible in view of the low circulating concentrations (fmol/ml). However, the kidney is likely to be an exception.
We have found that plasma NTproCNP is highly correlated with serum creatinine concentrations (Schouten et al. 2011) even at creatinine concentrations within the normal reference range, suggesting that the peptide is subject to glomerular filtration. In previous studies in young lambs, we have also documented a significant arteriovenous gradient for NTproCNP across the kidney, indicating renal extraction of the peptide ). The present findings of increasing NTproCNP both in plasma and in renal tissue on day 7 and the very strong correlation (rZ0 . 95) between the two measurements in the combined data are consistent with the above observations. Just as circulating (liver-derived) IGF1 is extracted by the kidney (D'Ercole et al. 1984 , Kimura et al. 1994 ) and appears to induce gene expression of renal growth factors (Fan et al. 2009) , it is possible that CNP plays a similar role in the immature kidney. While contributions of CNPs from the kidney and other non-skeletal tissues to circulating levels are likely, our current observations support previous findings of a positive venoarterial CNP gradient across bone dense tissues ) and the correlation of NTproCNP with linear growth velocity in a wide variety of clinical settings. Still to be established are the precise cells within growth plate-related tissues secreting the peptide and how it enters the circulation given the avascular nature of cartilage tissue. However, recent reports (Kake et al. 2009) show that plasma circulating levels of CNP around 7 . 5 pg/ml (3 . 4 pmol/l), achieved by expressing the SAP CNP transgene in the liver, significantly increase skeletal growth, suggesting that interchange between growth plate tissues and plasma can occur in vivo. Future studies directed to localise the peptide by immunohistochemistry within growth plate tissues as well as to determine the specific sites of CNP gene expression are now required. Such studies, as shown previously in the context of IGF1 (Reinecke et al. 2000) , should clarify the links between cell-specific sites of production and auto/paracrine actions, but because of the much lower peptide abundance will likely prove to be more challenging. The process by which GH stimulates CNP secretion was not addressed in this study, but the failure of short-term GH to affect plasma NTproCNP (or skeletal growth) in rapidly growing healthy lambs despite the large increases in plasma IGF1 suggests that neither GH nor IGF1 directly stimulates CNP gene expression. A range of genes or transcription factors including transforming growth factor b, fibroblast growth factor, PDGF bb, TSC 22 (Suga et al. 1992 , Mendonca et al. 2010 ) and KLF2 (Parmar et al. 2006 ) are reported to increase CNP mRNA in vascular endothelial cells, but little is known of the mechanisms regulating CNP gene expression within the growth plate. Presumably downstream effectors of GH and IGF1, and possibly GH-induced mechanosensitive pathways (Zhang et al. 2011) , for example, by stimulating KLF2 (Cameron et al. 2009) , are involved.
As found previously in other species, molar ratios of NTproCNP to CNP in rat plasma (30-40) greatly exceed those in tissues of origin where ratios (kidney excepted) are closer to 1. These observations are consistent with substantial loss of CNP en route to or within the circulation and the slower clearance of NTproCNP from plasma. In fact, the tissue NTproCNP to CNP ratio is likely to be even lower than unity since CNP 53 (the likely bioactive form of the peptide in tissues) shows only one-third (Kake et al. 2009 ) of the immunoreactivity of CNP 22 (the form present in the circulation), using the same antiserum as employed in this study. Whereas no statistically significant association of epiphyseal CNP content was found with plasma CNP, there were strong associations of plasma CNP with three separate measures of linear growth (Fig. 4D-F) . Conceivably, variable degradation by local factors (such as the natriuretic peptide clearance receptor and neprilysin abundance in growth plate tissue) or variable extraction of CNP 53 (known to be strongly hydrophobic) from growth plate tissue accounts for this discrepancy.
In conclusion, the linear growth response of GHD rodent pups to GH is associated with rapid and sustained increase in plasma concentrations of CNPs that precede measurable changes in linear growth. The associated and sustained increase in the abundance of CNPs in growth plate tissues during the course of GH treatment is consistent with CNP's important role in promoting endochondral growth. Collectively, these findings add to previous work supporting the use of CNP analogues as treatment for growth disorders refractory to current therapies, and also support the potential use of CNP assays in the clinic as biomarkers of growth plate activity.
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